This database contains 67 studies, archived under the term: "mental status schedule"
Click here to filter this large number of results.
Survival of community-dwelling older people: the effect of cognitive impairment and social engagement
Objectives: To examine the association and interaction between cognitive impairment and social support and mortality.; Design: Prospective cohort study.; Setting: Fifty-three family practices in the United Kingdom.; Participants: Community-dwelling people (aged > or =75) participating in the Medical Research Council Trial of the Assessment and Management of Older People in the Community (10,720 individual subjects […]
Levodopa use and sleep in patients with dementia with Lewy bodies
Sleep disturbance and excessive daytime somnolence (EDS) are features of Parkinson’s disease (PD) and dementia with Lewy bodies (DLB) that may be influenced by dopamine replacement therapy. The effect of levodopa on sleep and EDS in DLB is unknown and unclear in PD. The aim of this study is to determine if levodopa treatment alters […]
A randomized cross-over study of a traditional Japanese medicine (kampo), yokukansan, in the treatment of the behavioural and psychological symptoms of dementia
Mizukami, Katsuyoshi,
Asada, Takashi,
Kinoshita, Toru,
Tanaka, Katsuaki,
Sonohara, Kazuki,
Nakai, Ryuhei,
Yamaguchi, Kiyoshi,
Hanyu, Haruo,
Kanaya, Kiyoshi,
Takao, Tetsuya,
Okada, Masakatsu,
Kudo, Sumio,
Kotoku, Hayato,
Iwakiri, Masahiko,
Kurita, Hirofumi,
Miyamura, Toshihiro,
Kawasaki, Yosuke,
Omori, Koji,
Shiozaki, Kazumasa,
Odawara, Toshinari,
Suzuki, Tatsuya,
Yamada, Shizuru,
Nakamura, Youichi,
Toba, Kenji
The effectiveness and safety of yokukansan (TJ-54), a traditional Japanese medicine (kampo) for the treatment of the behavioural and psychological symptoms of dementia (BPSD), were evaluated in 106 patients diagnosed as having Alzheimer’s disease (AD) (including mixed-type dementia) or dementia with Lewy bodies. Patients were randomly assigned to group A (TJ-54 treatment in period I […]
Vitamin E paradox in Alzheimer’s disease: it does not prevent loss of cognition and may even be detrimental
Lloret, Ana,
Badía, Mari-Carmen,
Mora, Nancy J.,
Pallardó, Federico V.,
Alonso, Maria-Dolores,
Viña, Jose
There is controversy as to whether vitamin E is beneficial in Alzheimer’s disease (AD). In this study, we tested if vitamin E prevents oxidative stress and loss of cognition in AD. Fifty-seven AD patients were recruited and divided in two groups: placebo or treated with 800 IU of vitamin E per day for six months. […]
Randomized controlled trial of memantine in dementia associated with Parkinson’s disease
The objective of this study is to investigate the safety and tolerability of memantine, a glutamatergic modulator, in patients suffering from dementia associated with Parkinson’s disease (PDD), an increasingly common complication of PD. This was a 22-week trial of 25 participants with a DSM-IV diagnosis of PDD who were randomized to either placebo or 20 […]
Cognitive decline from estimated premorbid status predicts neurodegeneration in Alzheimer’s disease
This study investigated the relationship between premorbid and current cognitive function with respect to the clinical features of patients with various types of neurodegeneration in the form of Alzheimer’s disease (AD), mild cognitive impairment (MCI), and subjective cognitive impairment (SCI), as compared with a healthy control group (C). Clinical features (MMSE, cognitive and depressive symptoms), […]
Effect of music on pain for home-dwelling persons with dementia
The purpose of this study was to investigate the effect of music on pain for home-dwelling persons with dementia. A quasiexperimental design was used. Fifteen subjects listened to their preferred music for 30 minutes before peak agitation time, for 2 days per week, followed by no music for 2 weeks. The process was repeated once. […]
Lithium trial in Alzheimer’s disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study
Hampel, Harald,
Ewers, Michael,
Bürger, Katharina,
Annas, Peter,
Mörtberg, Anette,
Bogstedt, Anna,
Frölich, Lutz,
Schröder, Johannes,
Schönknecht, Peter,
Riepe, Matthias W.,
Kraft, Inga,
Gasser, Thomas,
Leyhe, Thomas,
Möller, Hans-Jürgen,
Kurz, Alexander,
Basun, Hans
Objective: Lithium, a first-line drug for the treatment of bipolar depression, has recently been shown to regulate glycogen synthase kinase-3 (GSK-3), a kinase that is involved in the phosphorylation of the tau protein. Since hyperphosphorylation of tau is a core pathological feature in Alzheimer’s disease, lithium-induced inhibition of GSK-3 activity may have therapeutic effects in […]
A randomized, placebo-controlled trial of latrepirdine in Huntington disease
Kieburtz, Karl,
McDermott, Michael P.,
Voss, Tiffini S.,
Corey-Bloom, Jody,
Deuel, Lisa M.,
Dorsey, E. Ray,
Factor, Stewart,
Geschwind, Michael D.,
Hodgeman, Karen,
Kayson, Elise,
Noonberg, Sarah,
Pourfar, Michael,
Rabinowitz, Karen,
Ravina, Bernard,
Sanchez-Ramos, Juan,
Seely, Lynn,
Walker, Francis,
Feigin, Andrew
Objectives: To evaluate the safety and tolerability of latrepirdine in Huntington disease (HD) and explore its effects on cognition, behavior, and motor symptoms.; Design: Double-blind, randomized, placebo-controlled trial.; Setting: Multicenter outpatient trial.; Participants: Ninety-one participants with mild to moderate HD enrolled at 17 US and UK centers from July 18, 2007, through July 16, 2008.; […]